Amryt Pharma plc logo
Amryt Pharma plc AMYT
report update icon

Quarterly report 2021-Q4
added 05-23-2026

Amryt Pharma plc Net Debt | AMYT

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Amryt Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-107 M -113 M -65.6 M 7.78 M -11.2 M -8.7 M -16.8 M -17.4 M -31.5 M -239 K -1.61 K

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
7.78 M -113 M -33.1 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
14.4 M - - $ 24.9 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-29.9 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-76.6 M - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
-103 M - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
17.3 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
-19.3 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
-283 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
-165 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
-136 M $ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
-81 M - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-3.5 M - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
-1.97 M $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
-9.68 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
-64.8 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
-34.5 M - - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
-119 M - -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
1.5 M - -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
-34.8 M - - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
-990 M - 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
-398 M - -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-23.8 M - -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
-11.5 M - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
-278 M - - $ 69.7 B britainBritain
Atreca Atreca
BCEL
33.1 M - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
-4.07 M - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
-36.8 M - - $ 109 M usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
-260 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
-11.1 M - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
-188 M - - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
7.16 M - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
489 K - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
-1.98 M - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
-33.5 M - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
-4.65 M - 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-114 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-236 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
-29.4 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
-2.42 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
-45.8 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
-6.03 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
-25.6 M - - $ 728 M usaUSA